###begin article-title 0
###xml 23 30 23 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A</italic>
###xml 97 103 <span type="species:ncbi:9606">Humans</span>
###xml 108 112 <span type="species:ncbi:10090">Mice</span>
A Prevalent Variant in PPP1R3A Impairs Glycogen Synthesis and Reduces Muscle Glycogen Content in Humans and Mice
###end article-title 0
###begin article-title 1
New Insights into Impaired Muscle Glycogen Synthesis: More a Problem of Muscle Contractility Than of Glucose Tolerance
###end article-title 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 247 254 247 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A</italic>
###xml 275 277 275 277 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 70 75 <span type="species:ncbi:9606">Human</span>
###xml 350 362 <span type="species:ncbi:9606">participants</span>
Stored glycogen is an important source of energy for skeletal muscle. Human genetic disorders primarily affecting skeletal muscle glycogen turnover are well-recognised, but rare. We previously reported that a frameshift/premature stop mutation in PPP1R3A, the gene encoding RGL, a key regulator of muscle glycogen metabolism, was present in 1.36% of participants from a population of white individuals in the UK. However, the functional implications of the mutation were not known. The objective of this study was to characterise the molecular and physiological consequences of this genetic variant.
###end p 3
###begin title 4
Methods and Findings
###end title 4
###begin p 5
###xml 144 146 144 146 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sup>
###xml 222 223 222 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 271 272 271 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 463 464 463 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 104 116 <span type="species:ncbi:9606">participants</span>
###xml 206 211 <span type="species:ncbi:9606">human</span>
###xml 323 327 <span type="species:ncbi:10090">Mice</span>
###xml 457 461 <span type="species:ncbi:10090">mice</span>
###xml 502 506 <span type="species:ncbi:10090">mice</span>
In this study we found a similar prevalence of the variant in an independent UK white population of 744 participants (1.46%) and, using in vivo 13C magnetic resonance spectroscopy studies, demonstrate that human carriers (n = 6) of the variant have low basal (65% lower, p = 0.002) and postprandial muscle glycogen levels. Mice engineered to express the equivalent mutation had similarly decreased muscle glycogen levels (40% lower in heterozygous knock-in mice, p < 0.05). In muscle tissue from these mice, failure of the truncated mutant to bind glycogen and colocalize with glycogen synthase (GS) decreased GS and increased glycogen phosphorylase activity states, which account for the decreased glycogen content.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
###xml 6 13 6 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A</italic>
###xml 179 184 <span type="species:ncbi:9606">human</span>
Thus, PPP1R3A C1984DeltaAG (stop codon 668) is, to our knowledge, the first prevalent mutation described that directly impairs glycogen synthesis and decreases glycogen levels in human skeletal muscle. The fact that it is present in approximately1 in 70 UK whites increases the potential biomedical relevance of these observations.
###end p 7
###begin p 8
###xml 69 76 69 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A</italic>
###xml 98 110 <span type="species:ncbi:9606">participants</span>
###xml 209 214 <span type="species:ncbi:9606">human</span>
Stephen O'Rahilly and colleagues describe the effect of a mutation inPPP1R3A, present in 1.36% of participants from one UK population, that directly impairs glycogen synthesis and decreases glycogen levels in human skeletal muscle.
###end p 8
###begin title 9
Editors' Summary
###end title 9
###begin title 10
Background.
###end title 10
###begin p 11
###xml 1173 1176 1173 1176 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL,</sub>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human body gets the energy it needs for day-to-day living from food in a process called metabolism. However, not all the energy released by metabolism is used immediately. Some is stored in skeletal muscles as glycogen, a glucose polymer that is used during high intensity exercise. After eating, chemicals in the digestive system release glucose (a type of sugar) from food into the bloodstream where it triggers insulin release from the pancreas. Insulin instructs muscle, liver and fat cells to remove glucose from the bloodstream to keep the amount of sugar in the blood at a safe level. The cells use the glucose immediately as fuel or convert it into glycogen or fat for storage. Glycogen turnover (the depletion and replacement of glycogen stores) is tightly controlled by glycogen synthase and glycogen phosphorylase, enzymes that make and destroy glycogen, respectively. A third enzyme called protein phosphatase 1 promotes net glycogen synthesis by activating glycogen synthase and inactivating glycogen phosphorylase. The activity of protein phosphatase 1 is regulated by a family of "targeting subunits." In muscle, one of these targeting subunits, called RGL, facilitates protein phosphatase 1 action on glycogen synthase and glycogen phosphorylase.
###end p 11
###begin title 12
Why Was This Study Done?
###end title 12
###begin p 13
###xml 523 530 523 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A</italic>
###xml 555 557 555 557 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 601 611 601 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 716 718 716 718 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 769 771 769 771 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 14 19 <span type="species:ncbi:9606">human</span>
Several known human genetic disorders affect the breakdown of muscle glycogen but few genetic changes (mutations) have been found that decrease the synthesis of muscle glycogen. Researchers are interested in discovering mutations that affect glycogen turnover and other aspects of metabolism because some of these may be involved in the development of diabetes, an important metabolic disorder characterized by high blood sugar levels. In this study, the researchers have investigated how a recently identified mutation in PPP1R3A, the gene that encodes RGL, affects glycogen synthesis. This mutation-PPP1R3A FS-was previously found in 1.36% of a UK white population. It causes the production of a short version of RGL that lacks the part of the molecule that tethers RGL to a cellular structure called the sarcoplasmic reticulum but leaves its glycogen binding domain intact.
###end p 13
###begin title 14
What Did the Researchers Do and Find?
###end title 14
###begin p 15
###xml 16 26 16 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 368 378 368 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 494 496 494 496 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sup>
###xml 814 824 814 824 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 975 977 975 977 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 296 302 <span type="species:ncbi:9606">people</span>
###xml 353 359 <span type="species:ncbi:9606">people</span>
###xml 631 637 <span type="species:ncbi:9606">people</span>
###xml 796 800 <span type="species:ncbi:10090">mice</span>
###xml 844 849 <span type="species:ncbi:9606">human</span>
###xml 866 870 <span type="species:ncbi:10090">mice</span>
###xml 1005 1009 <span type="species:ncbi:10090">mice</span>
To confirm that PPP1R3A FS is a common mutation in the UK white population, the researchers sequenced the gene in 744 healthy adults enrolled in the Oxford Biobank (which hopes to uncover metabolically important genetic variations by monitoring the health of a large number of 30- to 50-year-old people from whom DNA has been collected). 1.46% of these people had the PPP1R3A FS mutation. To examine glycogen storage in carriers of the mutation, the researchers used a technique called in vivo 13C magnetic resonance spectroscopy. Basal muscle glycogen levels and those reached after a meal were lower in these individuals than in people without the mutation but their blood sugar and insulin levels were normal. Finally, to examine how the mutation reduces muscle glycogen, the researchers made mice carrying the PPP1R3A FS mutation. Like the human carriers, these mice had less glycogen than normal in their muscles. Unexpectedly, in biochemical experiments the truncated RGL protein made by the mutant mice did not bind to glycogen or co-localize with glycogen synthase. This lack of binding decreased the activity of glycogen synthase and increased the activity of glycogen phosphorylase, thus decreasing muscle glycogen.
###end p 15
###begin title 16
What Do These Findings Mean?
###end title 16
###begin p 17
###xml 28 38 28 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 751 761 751 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 921 931 921 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 150 155 <span type="species:ncbi:9606">human</span>
###xml 255 260 <span type="species:ncbi:9606">human</span>
###xml 797 803 <span type="species:ncbi:9606">people</span>
These findings identify the PPP1R3A FS mutation as the first prevalent mutation known to impair glycogen synthesis and to decrease glycogen levels in human skeletal muscles. They also confirm that this mutation is very common in UK whites. Although these human carriers do not report any exercise intolerance, detailed studies are needed to test whether the mutation has any effect on skeletal muscle performance. In addition, suggest the researchers, the mutation might be involved in the development of type 2 diabetes. Impaired insulin-stimulated glycogen synthesis, which is a feature of insulin-resistant muscle and liver cells, is thought to be a key event in the development of type 2 diabetes. Although some previous results indicate that the PPP1R3A FS mutations can sometimes predispose people to develop insulin resistance, only a large population-based study in multiple ethnic groups will reveal whether the PPP1R3A FS mutation has an important impact on the development of type 2 diabetes.
###end p 17
###begin title 18
Additional Information.
###end title 18
###begin p 19
Please access these Web sites via the online version of this summary at .
###end p 19
###begin p 20
Wikipedia has pages on  and on  (note that Wikipedia is a free online encyclopedia that anyone can edit; available in several languages)
###end p 20
###begin p 21
The MedlinePlus encyclopedia provides information about  (in English and Spanish)
###end p 21
###begin p 22
###xml 45 50 <span type="species:ncbi:9606">human</span>
The  is looking for genetic variations among human populations that are associated with metabolic and other disorders
###end p 22
###begin p 23
Web sites are available with brief descriptions of the research programs of  and
###end p 23
###begin title 24
Introduction
###end title 24
###begin p 25
###xml 212 219 212 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A</italic>
###xml 279 289 275 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 291 292 287 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b001">1</xref>
###xml 360 362 356 358 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 377 378 373 374 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sub>
###xml 412 413 408 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b002">2</xref>
###xml 414 415 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b003">3</xref>
###xml 423 425 419 421 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 569 570 565 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b004">4</xref>
###xml 609 610 605 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b005">5</xref>
###xml 637 638 633 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b006">6</xref>
###xml 893 894 889 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b007">7</xref>
###xml 895 896 891 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b009">9</xref>
###xml 929 936 925 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppp1r3a</italic>
###xml 996 998 992 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b010">10</xref>
###xml 1010 1012 1006 1008 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 1071 1073 1067 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b011">11</xref>
###xml 1080 1090 1076 1086 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 1299 1300 1295 1296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b004">4</xref>
###xml 1414 1424 1410 1420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 1478 1483 1474 1479 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 1587 1588 1583 1584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b001">1</xref>
###xml 1602 1607 1598 1603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 1683 1693 1679 1689 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 1766 1768 1762 1764 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 1966 1973 1962 1969 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A</italic>
###xml 69 74 <span type="species:ncbi:9606">human</span>
###xml 947 951 <span type="species:ncbi:10090">mice</span>
###xml 1028 1032 <span type="species:ncbi:10090">mice</span>
###xml 1136 1147 <span type="species:ncbi:7116">large white</span>
The dissection of the genetic basis for interindividual variation in human metabolism is a major goal of contemporary metabolic research. Recently we identified a novel frameshift (FS) premature stop mutation in PPP1R3A (C1984DeltaAG; stop codon 668; referred to subsequently as PPP1R3A FS [1]), a gene encoding the muscle-specific glycogen-targeting subunit RGL (also called GM) of protein phosphatase 1 (PP1) [2,3]. The RGL polypeptide contains an extended C-terminal tail with a short hydrophobic segment responsible for association with the sarcoplasmic reticulum [4] as well as carbohydrate- (glycogen) [5] and PP1-binding domains [6] in the N-terminal 240 residues. The latter facilitate localization of the catalytic subunit of the phosphatase (PP1c) to glycogen where it dephosphorylates glycogen synthase (GS) and glycogen phosphorylase (GP), and thereby promotes glycogen synthesis [7-9]. We have previously shown that Ppp1r3a-disrupted mice exhibit a 90% reduction in muscle glycogen [10], whereas RGL-overexpressing mice accumulate excess glycogen in muscle [11]. The PPP1R3A FS mutation, which was initially described in a large white kindred, results in a mutant protein lacking the long C-terminal tail including the hydrophobic segment that tethers it to the sarcoplasmic reticulum [4]. In that pedigree, severe insulin resistance was restricted to individuals who were doubly heterozygous for the PPP1R3A FS variant and an unlinked loss-of-function mutation in PPARG (AAA553T; stop codon 186), which encodes a key transcriptional regulator of adipocyte differentiation [1]. Whilst the PPARG variant was uniquely present in that kindred, the allelic frequency of the PPP1R3A FS variant was 1.36% in a population of UK whites. Although the truncated RGL was shown to be mistargeted within the cell, its functional impact on glycogen synthesis was not determined. Here we sought to characterise the molecular and in vivo biological consequences of the PPP1R3A FS variant.
###end p 25
###begin title 26
Methods
###end title 26
###begin p 27
###xml 179 181 179 181 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 126 138 <span type="species:ncbi:9606">participants</span>
###xml 186 190 <span type="species:ncbi:10090">mice</span>
###xml 482 487 <span type="species:ncbi:10090">mouse</span>
All human studies were approved by the relevant Local Research Ethics Committees (Cambridge, Oxford, and Nottingham), and all participants provided written informed consent. The RGL kin mice were generated by Cheryl Bock at the Comprehensive Cancer Center Transgenic Facility, Duke University, Durham, North Carolina, United States. All animals were maintained on a 12:12 h light-dark cycle in a temperature- and humidity-controlled facility with free access to food and water. All mouse studies were conducted in accordance with federal guidelines and were approved by the Institutional Animal Use and Care Committees of Indiana, Duke, and Yale Universities.
###end p 27
###begin title 28
Oxford Biobank and Genotyping
###end title 28
###begin p 29
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b012">12</xref>
###xml 85 88 <span type="species:ncbi:9606">men</span>
###xml 93 98 <span type="species:ncbi:9606">women</span>
###xml 153 165 <span type="species:ncbi:9606">participants</span>
###xml 385 397 <span type="species:ncbi:9606">Participants</span>
The Oxford Biobank consists of an age-stratified random sample of 30- to 50-year-old men and women from Oxfordshire (total population 615,200) [12]. All participants screened were classified as "white" by the researchers. Exclusion criteria included mental or physical ill health, alcohol- or drug-related problems, and significantly abnormal liver or renal function tests or anaemia. Participants attended a screening visit at the Clinical Research Unit, where blood tests were performed and basic anthropometric data recorded. DNA was stored from the visit and consent obtained to allow subsequent genotyping for genetic variants of potential metabolic importance. Primer sequences used for genotyping are available upon request.
###end p 29
###begin title 30
###xml 50 55 <span type="species:ncbi:9606">Human</span>
###xml 56 68 <span type="species:ncbi:9606">Participants</span>
Determination of Muscle Glycogen Concentration in Human Participants
###end title 30
###begin p 31
###xml 24 34 24 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 58 65 58 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0050027-t001">Table 1</xref>
###xml 157 162 157 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 279 280 279 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 341 342 341 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 371 373 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b013">13</xref>
###xml 515 517 515 517 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sup>
###xml 597 598 597 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 943 945 943 945 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sup>
###xml 975 976 975 976 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 1009 1011 1009 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b013">13</xref>
###xml 290 302 <span type="species:ncbi:9606">participants</span>
###xml 376 388 <span type="species:ncbi:9606">Participants</span>
Six volunteers with the PPP1R3A FS mutation were studied (Table 1). Two of these individuals were doubly heterozygous for an additional unlinked mutation in PPARG and had severe insulin resistance. The results from these individuals were compared to volunteers without diabetes (n = 9) and participants with diet-controlled type 2 diabetes (n = 9) from a previous study [13]. Participants abstained from vigorous exercise and alcohol for 3 d prior to the study and each fasted for 12 h prior to the study. Baseline 13C measurements for muscle glycogen were taken prior to the first standard meal (t = 0), which consisted of 190.5 g carbohydrate, 41.0 g fat, and 28.8 g protein, totalling 1,253 kcal. Further measurements were taken at 60, 120, and 240 min, after which another standard meal of similar composition was given, followed by measurements at 300, 360, and 480 min. All glycogen measurements were performed at 3.0T, using a circular 13C surface coil and quadrature 1H coils as described previously [13]. Blood samples were taken for glucose and insulin measurements at the same times as the spectra.
###end p 31
###begin p 32
###xml 41 53 <span type="species:ncbi:9606">Participants</span>
Demographic Characteristics of the Study Participants
###end p 32
###begin title 33
###xml 23 25 23 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 35 39 <span type="species:ncbi:10090">Mice</span>
Generation of Mutant, RGL Knock-in Mice
###end title 33
###begin p 34
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppp1r3a</italic>
###xml 176 177 171 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b002">2</xref>
###xml 268 270 263 265 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 479 488 474 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050027-sg001">Figure S1</xref>
###xml 719 726 714 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppp1r3a</italic>
###xml 1607 1609 1590 1592 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 2706 2715 2689 2698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050027-sg002">Figure S2</xref>
###xml 2978 2987 2961 2970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050027-sg002">Figure S2</xref>
###xml 3364 3366 3347 3349 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 3608 3617 3591 3600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050027-sg002">Figure S2</xref>
###xml 657 662 <span type="species:ncbi:9606">human</span>
###xml 663 675 <span type="species:ncbi:9606">participants</span>
###xml 713 718 <span type="species:ncbi:10090">mouse</span>
###xml 1057 1062 <span type="species:ncbi:9606">human</span>
###xml 3128 3132 <span type="species:ncbi:10090">mice</span>
###xml 3164 3168 <span type="species:ncbi:10090">mice</span>
###xml 3232 3236 <span type="species:ncbi:10090">mice</span>
###xml 3276 3280 <span type="species:ncbi:10090">mice</span>
###xml 3424 3428 <span type="species:ncbi:10090">Mice</span>
The Ppp1r3a targeting vector was assembled by PCR-amplified and restriction enzyme-digested fragments from the lambda Fix 14-1-1 ES cell genomic DNA clone previously reported [2]. This clone is 13 kb and extends from 2 kb upstream of exon 2 to 7 kb downstream of the RGL stop codon. The short recombination arm fragment consists of 1.2 kb of intron 3 and was inserted upstream of the 5' LoxP site flanking the Neo cassette at the XhoI and NotI sites in the pPGKNeobpAlox2PGKDTA (Figure S1). The long recombination arm containing the FS mutation was constructed with three fragments. Part 1 was engineered to contain the FS premature stop codon found in the human participants at the corresponding position in the mouse Ppp1r3a by amplifying a region from 500 bp upstream of exon 4 to approximately 1,000 bp of exon 4. The following oligonucleotide primers were used: forward 5'-TTTGCTAGCGCCGTTGACAAGTAACATGAGCCTTAT-3' and reverse 5'-AAACCATGGTTATTCTCTCTTGATTTTCCGGGTTTCCAGAACGTTCCATTT-3'. The reverse primer encodes the altered six amino acids found in the human mutation followed by a stop codon and an NcoI site. Part 2 was a 2.2 kb NcoI-BstEII amplified fragment. Part 3 was the 4.6 kb restriction enzyme-digested BstEII-BStz171. The three fragments, totalling 8.3 kb, were inserted downstream of the 3' LoxP site flanking the PGK-Neo gene at the NheI and EcoRV sites. Part 1 was completely sequenced to ensure that the correct mutation was introduced and that no unintended mutations were present. All junctions in the final construct were confirmed by sequencing and restriction enzyme digestion. The RGL kin targeting vector also contains the diphtheria toxin A gene (PGK-DTA) for selection against random integration. The vector was linearized at the unique AhdI site and electroporated into W4 ES cells. G418-resistant cell clones were initially screened for targeting by PCR with primers ADPR 424, 5'-GCTAGACTTGATGGTAAGTGTTCTGGTTGCACAG-3' outside of the short recombination arm and ADPR 422, 5'-CGCGAAGGGGCCACCAAAGAAGGGAGCCGGTTG-3', in the PGK-Neo region. Positive clones were further analyzed for the presence of the mutation by utilizing ADPR 425, 5'-CCCCGGAAATCAAGAGAGAATAACCATGG-3', which specifically recognizes the mutated sequence and not the corresponding wild type (WT), and ADPR 406, 5'-TGCGAATTCTCACCTGCCTTGAGCTTCGAGTTC-3' located downstream. From this double screen, two positive clones were identified and correct targeting was confirmed by Southern blots of ES cell genomic DNA digested with NheI. Two fragments of 10.3 and 3.4 kb, corresponding to the WT and to the targeted allele, respectively, were detected with the 5' probe, and 10.3 kb and 8.8 kb fragments with the 3' probe (Figure S2A). Both clones, confirmed to be correctly targeted, were expanded and electroporated with a PGK-NLS/Cre plasmid. Resulting clones were screened by PCR for excision of the Neo cassette (efficiency 40%, 73/190) and 12 were analyzed and confirmed by Southern blot (Figure S2B). Two clones, after karyotyping, were injected into C57Bl/6J blastocysts, which were then implanted in the uterus of pseudopregnant female mice. High-percentage male chimeric mice, as judged by the agouti colour coat, were mated with C57Bl/6J mice to determine germline transmission. F1 mice were backcrossed two more times into the C57Bl/6J background, before breeding the RGL kin heterozygotes to generate animals used in the study. Mice were genotyped by PCR with a pair of primers that straddle the residual loxP site as well as a pair of primers, one of which specifically hybridizes with the mutated nucleotides (Figure S2C).
###end p 34
###begin title 35
Enzyme Activity Assays
###end title 35
###begin p 36
###xml 64 66 64 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b010">10</xref>
###xml 239 244 239 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</sup>
###xml 460 461 452 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 588 590 579 581 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 610 612 601 603 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 667 669 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b014">14</xref>
###xml 790 792 781 783 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 808 810 799 801 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 886 888 877 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b015">15</xref>
###xml 963 965 953 955 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 987 989 977 979 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 1086 1088 1075 1077 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 1106 1108 1095 1097 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
The GS and GP activities were measured as previously described [10]. Basically, powdered frozen tissue samples were homogenized in 30 volumes of buffer (50 mM Tris-HCl [pH 7.8], 10 mM EDTA, 2 mM EGTA, 100 mM NaF, 2 mM benzamidine, 0.1 mM Nalpha-p-tosyl-L-lysine chloromethyl ketone, 50 mM beta-mercaptoethanol, 0.5 mM PMSF, and 10 mug/ml leupeptin) using a Tissue Tearer Model 285-370 (Biospec Products) at maximal speed for 20 s. After centrifugation at 3,600g for 5 min, 30 mul of the supernatant was used for GS and GP assays. GS activity was determined by measuring incorporation of [14C]glucose from UDP-[14C]glucose into glycogen as described by Thomas et al. [14] in the absence or presence of 7.2 mM glucose-6-phosphate (G6P). GP activity was assayed by measuring incorporation of [14C]glucose from [14C]glucose-1-phosphate into glycogen in the absence or presence of 2 mM AMP [15]. One unit of GS is the amount of enzyme that incorporates 1 mumol/min of 14C-glucose from UDP-[U-14C]glucose into glycogen and 1 unit of GP, the amount of enzyme that incorporates 1 mumol/min of [14C]glucose from [U-14C]glucose-1-phosphate. Activity ratios represent the activity measured in the absence divided by that in the presence of the allosteric effectors G6P for GS or AMP for GP and provide an index of the phosphorylation state and hence, activity of the enzymes.
###end p 36
###begin title 37
Other procedures.
###end title 37
###begin p 38
###xml 192 199 192 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050027-se001">Text S1</xref>
Information about Western immunoblotting, immunoprecipitations, GST-GN pull-downs, glycogen pellets, glucose and insulin tolerance tests, and hyperinsulinemic-euglycemic clamps is included in Text S1.
###end p 38
###begin title 39
Statistical Analysis
###end title 39
###begin p 40
###xml 88 89 86 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 185 186 183 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
All data are expressed as mean +/- standard error of the mean (SEM). Two-tailed Student t-tests or one-way ANOVA plus Tukey HSD multiple comparisons were performed on data at a minimum p < 0.05 threshold.
###end p 40
###begin title 41
Results
###end title 41
###begin title 42
###xml 4 14 4 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
The PPP1R3A FS Mutation Is Prevalent in UK Whites and Impairs In Vivo Glycogen Synthesis
###end title 42
###begin p 43
###xml 88 98 88 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 226 228 226 228 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sup>
###xml 450 451 448 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 464 474 462 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 605 606 599 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 616 624 610 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050027-g001">Figure 1</xref>
###xml 628 630 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b013">13</xref>
###xml 745 746 737 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 826 834 816 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050027-g001">Figure 1</xref>
###xml 867 877 857 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 1034 1044 1024 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 1055 1063 1045 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050027-g001">Figure 1</xref>
###xml 1069 1070 1059 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050027-g001">1</xref>
###xml 1223 1233 1213 1223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 1248 1256 1238 1246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG FS</italic>
###xml 1284 1292 1274 1282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050027-g001">Figure 1</xref>
###xml 1296 1297 1286 1287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b001">1</xref>
###xml 1381 1389 1371 1379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050027-g001">Figure 1</xref>
###xml 1395 1396 1385 1386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050027-g001">1</xref>
###xml 1313 1325 <span type="species:ncbi:9606">participants</span>
We genotyped 744 adults without diabetes from an Oxfordshire Biobank and found that the PPP1R3A FS allelic frequency was 1.46%. To determine the in vivo effects of this truncated variant on skeletal muscle glycogen synthesis, 13C magnetic resonance spectroscopy studies were undertaken in nondiabetic volunteers of known genotype from the Oxfordshire study. Baseline muscle glycogen concentration (23.9 +/- 14.7 mmol/l) was significantly lower (65%, p = 0.002) in PPP1R3A FS heterozygotes than in nondiabetic volunteers (68.9 +/- 4.1 mmol/l) and even volunteers with type 2 diabetes (57.1 +/- 3.6 mmol/l, p = 0.01) (Figure 1A) [13]. After a meal, mean glycogen concentrations increased in nondiabetic volunteers (97.1 +/- 7.0 mmol/l at 240 min; p = 0.005). Glycogen levels peaked at 108.0 +/- 11.6 mmol/l after a second meal (Figure 1A). This response was blunted in PPP1R3A FS carriers. Despite the significant differences in muscle glycogen levels, plasma glucose and insulin measurements were similar in nondiabetic volunteers and PPP1R3A FS carriers (Figure 1B and 1C). Muscle glycogen concentrations were decreased to a similar extent in two severely insulin-resistant individuals who were doubly heterozygous for the PPP1R3A FS variant and a PPARG FS loss-of-function mutation (Figure 1A) [1]. Both digenic participants were glucose intolerant and markedly hyperinsulinemic (Figure 1B and 1C).
###end p 43
###begin title 44
###xml 6 16 6 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human PPP1R3A FS Carrier Phenotype
###end title 44
###begin p 45
###xml 82 92 82 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 179 189 179 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 200 201 200 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 279 280 279 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 351 352 351 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 447 457 447 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 462 470 462 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG FS</italic>
###xml 66 72 <span type="species:ncbi:9606">humans</span>
###xml 310 322 <span type="species:ncbi:9606">participants</span>
###xml 404 416 <span type="species:ncbi:9606">participants</span>
(A) Muscle glycogen, (B) blood glucose, and (C) insulin levels in humans with the PPP1R3A FS mutation before and after two standardised meals (given at 60 and 240 min). Data from PPP1R3A FS carriers (n = 4; open circles) are compared with those from volunteers without diabetes (n = 9; solid squares) and from participants with type 2 diabetes (T2DM; n = 9; filled triangles). Mean data from two digenic participants (double heterozygotes for the PPP1R3A FS and PPARG FS) are included in graphs (A) and (B). Mean fasting insulin levels from the two digenic individuals were 199, 5,744, 9,534, 1,303, 13,689, and 10,291 pmol/l, too high to include in (C), at 0, 60, 120, 240, 360, and 480 minutes, respectively.
###end p 45
###begin title 46
###xml 18 28 18 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice Carrying the PPP1R3A FS Mutation Have Abnormal Glycogen Metabolism
###end title 46
###begin p 47
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppp1r3a FS</italic>
###xml 25 27 25 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 188 189 188 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b001">1</xref>
###xml 207 214 207 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppp1r3a</italic>
###xml 402 411 402 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050027-sg001">Figure S1</xref>
###xml 531 538 531 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppp1r3a</italic>
###xml 558 562 558 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LoxP</italic>
###xml 644 646 644 646 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 789 791 789 791 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 794 796 794 796 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 805 813 805 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050027-g002">Figure 2</xref>
###xml 963 965 963 965 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 1078 1080 1078 1080 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 1176 1184 1164 1172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050027-g002">Figure 2</xref>
###xml 1236 1238 1224 1226 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 1386 1388 1374 1376 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 18 22 <span type="species:ncbi:10090">mice</span>
###xml 67 72 <span type="species:ncbi:9606">human</span>
###xml 201 206 <span type="species:ncbi:10090">mouse</span>
###xml 362 367 <span type="species:ncbi:10090">mouse</span>
###xml 418 422 <span type="species:ncbi:10090">mice</span>
###xml 1361 1366 <span type="species:ncbi:10090">mouse</span>
Ppp1r3a FS mutant mice (RGL kin) were generated by introducing the human mutation, in which deletion of two base pairs results in six altered amino acids before encountering a stop codon [1], into the mouse Ppp1r3a locus. Therefore, a nucleotide sequence encoding the six altered amino acids and a stop codon were introduced at the corresponding position in the mouse gene by homologous recombination (Figure S1). All mice used in the studies were backcrossed three or four generations into the C57BL6/6J background. The resulting Ppp1r3a locus contains one LoxP site in intron 3 and the frameshift mutation in exon 4. The predicted truncated RGL polypeptide consists of 634 residues with a Mr of 72,000. Western blotting of skeletal muscle extracts confirmed expression of the truncated RGL (RGL trunc) (Figure 2A), which on SDS-PAGE migrates with an apparent Mr of 83,000, higher than predicted. This altered gel migration is consistent with the properties of RGL, which as the full-length form also has slower electrophoretic mobility (160 kDa) than predicted (123 kDa). WT RGL was decreased by approximately50% in knock-in heterozygotes and was absent in the homozygotes (Figure 2A). The seemingly stronger signal of the truncated RGL protein is a reflection of the lower efficiency of electrophoretic transfer of the full-length protein. From heterozygous mouse intercrosses, WT, RGL kin heterozygotes and homozygotes were born at the expected mendelian ratio (1:2:1; WT 35, heterozygotes 81, and homozygotes 39). Growth, weight, and lean and fat mass were similar in all groups of animals up to the age of 9 mo (unpublished data).
###end p 47
###begin title 48
###xml 31 33 31 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 57 61 <span type="species:ncbi:10090">Mice</span>
Muscle Glycogen Metabolism in RGL Knock-in and Wild-Type Mice
###end title 48
###begin p 49
###xml 5 7 5 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 60 62 60 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 87 89 87 89 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 105 107 105 107 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 130 132 130 132 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 202 204 202 204 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 207 209 207 209 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 142 146 <span type="species:ncbi:10090">mice</span>
(A) RGL Western blots of skeletal muscle extracts from WT, RGL knock-in heterozygous (RGL kin het), and RGL knock-in homozygous (RGL kin hom) mice. The predicted molecular weight (MW) of the truncated RGL (RGL trunc, 643 amino acids) is 72,000 but it migrates on SDS polyacrylamide gel electrophoresis with an apparent MW of 83,000.
###end p 49
###begin p 50
###xml 111 113 111 113 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 138 140 138 140 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 156 158 156 158 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 181 183 181 183 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 193 197 <span type="species:ncbi:10090">mice</span>
(B) GS activity was assayed in the absence (-) or presence (+) of G6P in extracts of skeletal muscle from WT, RGL knock-in heterozygous (RGL kin het), and RGL knock-in homozygous (RGL kin hom) mice not injected or injected intraperitoneally with 5 mU/g insulin for 10 min (plain and chequered bars, respectively).
###end p 50
###begin p 51
(C) Total GS activity (mU/mg) measured in the presence of 7.2 mM G6P.
###end p 51
###begin p 52
(D) Glycogen phosphorylase (Ph) activity was assayed in the absence (-) or presence (+) of 2 mM AMP.
###end p 52
###begin p 53
(E) Total glycogen phosphorylase (Ph) activity (U/mg) measured in the presence of 2 mM AMP.
###end p 53
###begin p 54
(F) Glycogen content in muscle.
###end p 54
###begin p 55
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 21 22 21 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 49 50 49 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
n = 4-9 per group; * p < 0.05 versus WT basal; # p < 0.05 insulin versus basal.
###end p 55
###begin p 56
###xml 187 189 187 189 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 200 208 200 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050027-g002">Figure 2</xref>
###xml 292 300 292 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050027-g002">Figure 2</xref>
###xml 368 370 368 370 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 381 389 381 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050027-g002">Figure 2</xref>
###xml 395 396 395 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050027-g002">2</xref>
###xml 474 476 474 476 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 558 566 558 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050027-g002">Figure 2</xref>
###xml 732 740 728 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050027-g002">Figure 2</xref>
###xml 819 821 815 817 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 928 930 924 926 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 946 948 942 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b010">10</xref>
###xml 990 992 986 988 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 994 996 990 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b010">10</xref>
###xml 1020 1022 1016 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b016">16</xref>
###xml 1190 1192 1186 1188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b016">16</xref>
###xml 1193 1195 1189 1191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b017">17</xref>
###xml 1233 1235 1229 1231 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 1399 1401 1395 1397 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 1459 1461 1455 1457 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 194 198 <span type="species:ncbi:10090">mice</span>
###xml 375 379 <span type="species:ncbi:10090">mice</span>
###xml 481 485 <span type="species:ncbi:10090">mice</span>
###xml 700 704 <span type="species:ncbi:10090">mice</span>
###xml 940 944 <span type="species:ncbi:10090">mice</span>
###xml 1014 1018 <span type="species:ncbi:10090">mice</span>
###xml 1361 1365 <span type="species:ncbi:10090">mice</span>
###xml 1466 1470 <span type="species:ncbi:10090">mice</span>
The GS -/+ G6P activity ratio, which reflects the phosphorylation and activity state of the enzyme, was significantly decreased in muscle of both heterozygous (45%) and homozygous (68%) RGL kin mice (Figure 2B), whereas the GP -/+ AMP activity ratio was increased (30% and 50% respectively) (Figure 2D). Total GS and GP activities were also altered in the homozygous RGL kin mice (Figure 2C and 2E). As a consequence, muscle glycogen content was significantly decreased in RGL kin mice (40% and 55% reduction in heterozygotes and homozygotes, respectively) (Figure 2F). Notably, treatment with 5 mU/g insulin resulted in a similar extent of GS activation in WT, heterozygous, and homozygous knock-in mice (Delta increase 0.05-0.07; Figure 2B) indicating that neither the decreased glycogen level nor the truncation of RGL have a significant effect on GS activation by insulin. A similar response was previously observed in the RGL knockout mice [10]. Very low or absent muscle glycogen in RGL [10] and GS knockout mice [16], respectively, results in activation of AMP kinase, increased acetyl-CoA carboxylase phosphorylation, and a metabolic switch to increase muscle fatty acid oxidation [16,17]. AMP kinase phosphorylation in the RGL kin skeletal muscle revealed no detectable alterations (unpublished data), most likely because the glycogen content in these mice is significantly higher than in RGL knockouts. Liver glycogen content was similar in WT and RGL kin mice (unpublished data).
###end p 56
###begin title 57
###xml 37 42 <span type="species:ncbi:10090">Mouse</span>
The Mutant Protein Is Mistargeted in Mouse Skeletal Muscle
###end title 57
###begin p 58
###xml 15 17 15 17 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 156 157 156 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b005">5</xref>
###xml 158 159 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b006">6</xref>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b018">18</xref>
###xml 265 267 261 263 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 311 319 307 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050027-g003">Figure 3</xref>
###xml 364 372 360 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050027-g003">Figure 3</xref>
###xml 513 514 509 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b005">5</xref>
###xml 619 621 615 617 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 751 753 747 749 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 812 814 808 810 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 936 938 932 934 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 949 957 945 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050027-g003">Figure 3</xref>
###xml 963 964 959 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050027-g003">3</xref>
###xml 1191 1192 1187 1188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b009">9</xref>
###xml 1268 1270 1264 1266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b019">19</xref>
###xml 1329 1337 1325 1333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050027-g004">Figure 4</xref>
###xml 1375 1377 1371 1373 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 1409 1417 1405 1413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050027-g004">Figure 4</xref>
###xml 1575 1577 1571 1573 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 1712 1714 1708 1710 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 1754 1762 1750 1758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050027-g005">Figure 5</xref>
###xml 1785 1787 1781 1783 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 1904 1906 1900 1902 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 2078 2080 2074 2076 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 2306 2308 2302 2304 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 2485 2487 2481 2483 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 2553 2555 2549 2551 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 2590 2599 2586 2595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050027-sg003">Figure S3</xref>
###xml 2662 2664 2658 2660 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 294 299 <span type="species:ncbi:10090">mouse</span>
###xml 1526 1532 <span type="species:ncbi:10090">murine</span>
###xml 2739 2743 <span type="species:ncbi:10090">mice</span>
The truncated RGL retains PP1c-, glycogen-, and putative substrate-binding motifs, all of which are located in the first 240 amino acids encoded by exon 1 [5,6,18]. Western blot analyses showed that expression of PP1cdelta, the predominant isoform associated with RGL, was similar in all three mouse genotypes (Figure 3A). The level of GS was, however, decreased (Figure 3A), in keeping with the decreased total GS activity, most likely as a consequence of decreased glycogen, which is required for GS stability [5]. In order to gain insights into the mechanisms involved in the decreased glycogen content we assessed RGL binding to GS and glycogen. Antibodies directed against both the N-terminal 262 residues and C-terminal 325-1042 amino acids of RGL immunoprecipitated most of the full-length and truncated RGL (note that the truncation is at residue 643), but did not coimmunoprecipitate GS, indicating that neither WT nor mutant RGL binds GS (Figure 3B and 3C). This surprising result was confirmed by the reciprocal experiment in which GS was pulled down. We utilized a fusion protein (GST-GN[297-333] of GST and the residues 297-333 of glycogenin (GN), the glycogen priming protein [9], which interact with GS in two-hybrid assays and in coexpression studies [19]. While GST-GN(297-333) pulled down GS almost completely (Figure 4A), neither the WT nor the truncated RGL were found associated with GS (Figure 4B). Finally, high-speed ultracentrifugation was used to precipitate glycogen and sarcoplasmic reticulum from murine muscle extracts. The vast majority of WT RGL and GS, and a substantial proportion of GP were recovered in the high-speed pellet, indicating that they were all bound to glycogen (RGL also binds to sarcoplasmic reticulum) (Figure 5). However, truncated RGL was confined to the supernatant fraction, suggesting that the region between residue 637 and the C-terminal end of RGL may contribute to glycogen binding in addition to associating with sarcoplasmic reticulum. Although we cannot exclude the possibility that the inability of the truncated RGL to sediment in the high-speed pellet may be due to loss of the hydrophobic, membrane-associating domain, the fact that all the GS, which is well known to bind to glycogen, is present in the pellet argues that the ability of RGL trunc to bind glycogen is decreased. In addition, after solubilising membranes with Triton X-100 in the muscle extract, we still found a significant proportion of full-length RGL and all of the GS in the high-speed pellet, while the truncated RGL was primarily in the supernatant (Figure S3). Ultimately, the lack of colocalization of GS and truncated RGL accounts for the decreased GS activity and glycogen content in the mutant mice.
###end p 58
###begin title 59
###xml 25 27 25 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 30 32 30 32 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 61 63 61 63 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 117 119 117 119 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 144 146 144 146 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 161 163 161 163 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 186 188 186 188 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 198 202 <span type="species:ncbi:10090">Mice</span>
Interactions between WT RGL, RGL Knock-In Truncated Mutant (RGL trunc), and GS in Skeletal Muscle Extracts from WT, RGL Knock-In Heterozygous (RGL kin het) and RGL Knock-In Homozygous (RGL kin hom) Mice
###end title 59
###begin p 60
(A) Western blots of protein phosphatase-1 catalytic subunit delta (PP1cdelta) and GS in muscle extracts.
###end p 60
###begin p 61
###xml 23 25 23 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 44 46 44 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 75 77 75 77 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
(B) Western blots for RGL and GS following RGL immunoprecipitation with a RGL N-terminal antibody (Ab).
###end p 61
###begin p 62
###xml 23 25 23 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 44 46 44 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 75 77 75 77 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
(C) Western blots for RGL and GS following RGL immunoprecipitation with a RGL C-terminal antibody (Ab).
###end p 62
###begin title 63
Glycogen Synthase Pull Down
###end title 63
###begin p 64
###xml 168 170 164 166 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 180 182 176 178 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 205 207 201 203 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 311 313 307 309 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 316 318 312 314 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 217 221 <span type="species:ncbi:10090">mice</span>
GS was pulled down with GST-glycogenin-GST-GN(297-333)-fusion protein before and after alpha-amylase digestion of glycogen in skeletal muscle extracts from wild type (RGL WT) and RGL knock-in homozygous (RGL kin hom) mice. (A) GST-GN(297-333) pulls down almost all GS, but (B) neither the WT nor the truncated RGL (RGL trunc) was pulled down by GST-GN(297-333).
###end p 64
###begin title 65
###xml 1 3 1 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
RGL Western Blot Analysis of Skeletal Muscle Extracts
###end title 65
###begin p 66
###xml 94 96 94 96 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 131 133 131 133 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 213 214 213 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 274 276 274 276 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 160 164 <span type="species:ncbi:10090">mice</span>
Western blotting of high-speed supernatants and pellets of skeletal muscle extracts from WT, RGL knock-in heterozygous (het), and RGL knock-in homozygous (hom) mice. High speed (HS) ultracentrifugation at 100,0000g for 90 min was used to pellet glycogen. Western blots for RGL, GS, and GP were then performed on the supernatant and pellet fractions.
###end p 66
###begin title 67
###xml 56 58 56 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 68 72 <span type="species:ncbi:10090">Mice</span>
Glucose Tolerance and Insulin Sensitivity Is Normal in RGL Knock-in Mice
###end title 67
###begin p 68
###xml 67 69 67 69 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 93 95 93 95 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 113 121 113 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050027-g006">Figure 6</xref>
###xml 127 128 127 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050027-g006">6</xref>
###xml 136 138 136 138 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 516 518 516 518 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 542 550 542 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050027-g006">Figure 6</xref>
###xml 552 553 552 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050027-g006">6</xref>
###xml 694 702 694 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0050027-g006">Figure 6</xref>
###xml 536 540 <span type="species:ncbi:10090">mice</span>
Glucose and insulin tolerance were similar in male and female WT, RGL kin heterozygotes and RGL kin homozygotes (Figure 6A and 6B). As RGL is only expressed in muscle, we also performed hyperinsulinemic-euglycemic clamps (with radioisotope infusions) in order to independently assess peripheral (predominantly muscle) and hepatic insulin sensitivity. Glucose infusion rates, insulin-stimulated peripheral glucose turnover, and the ability of insulin to suppress endogenous glucose production were similar in WT and RGL kin heterozygous mice (Figure 6C-6F). Whole-body glycogen synthesis and glycolysis, as well as muscle insulin-stimulated glycogen synthesis, were also similar in both groups (Figure 6G).
###end p 68
###begin title 69
###xml 46 48 46 48 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 58 62 <span type="species:ncbi:10090">Mice</span>
Glucose Tolerance and Insulin Sensitivity in RGL Knock-in Mice
###end title 69
###begin p 70
###xml 100 102 100 102 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 127 129 127 129 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 145 147 145 147 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 165 167 165 167 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 177 181 <span type="species:ncbi:10090">mice</span>
(A) Glucose tolerance following intraperitoneal glucose (2 mg/g body weight) administration in WT, RGL knock-in heterozygous (RGL kin het), and RGL kin homozygous (RGL kin hom) mice.
###end p 70
###begin p 71
###xml 88 90 88 90 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 115 117 115 117 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 134 136 134 136 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 159 161 159 161 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 292 294 292 294 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 171 175 <span type="species:ncbi:10090">mice</span>
###xml 303 307 <span type="species:ncbi:10090">mice</span>
(B) Plasma glucose response to intraperitoneal insulin (0.75 mU/g body weight) in WT-, RGL knock-in heterozygous (RGL kin het)-, and RGL knock-in homozygous (RGL kin hom) mice. Peripheral and hepatic insulin sensitivity were assessed by means of hyperinsulinemic-euglycemic clamps in WT and RGL kin het mice (C-G). Glucose infusion rates (C); peripheral glucose turnover (D); and basal (E) and suppressed (F) endogenous glucose production (EGP) during hyperinsulinemic-euglycemic clamps.
###end p 71
###begin p 72
(G) Whole body (WB) glycolysis and glycogen synthesis were measured during the clamps.
###end p 72
###begin p 73
###xml 50 54 <span type="species:ncbi:10090">mice</span>
Data are expressed as mean values +/- SEM for 6-9 mice per treatment group.
###end p 73
###begin title 74
Discussion
###end title 74
###begin p 75
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b020">20</xref>
###xml 482 483 482 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b007">7</xref>
###xml 484 485 484 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b008">8</xref>
###xml 565 567 565 567 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 619 621 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b021">21</xref>
###xml 931 933 931 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b020">20</xref>
###xml 953 955 953 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b022">22</xref>
###xml 1067 1071 1067 1071 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 1477 1481 1477 1481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GYS1</italic>
###xml 1497 1499 1497 1499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b016">16</xref>
###xml 1500 1502 1500 1502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b023">23</xref>
###xml 1530 1537 1530 1537 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A</italic>
###xml 1665 1666 1665 1666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b009">9</xref>
###xml 1667 1669 1667 1669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b024">24</xref>
###xml 1670 1672 1670 1672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b027">27</xref>
###xml 1782 1792 1782 1792 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 2036 2037 2036 2037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b001">1</xref>
###xml 2132 2142 2132 2142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 632 637 <span type="species:ncbi:9606">human</span>
###xml 1435 1440 <span type="species:ncbi:9606">human</span>
###xml 1491 1495 <span type="species:ncbi:10090">mice</span>
###xml 1562 1568 <span type="species:ncbi:9606">humans</span>
Muscle glycogen is one of two major energy sources for muscle contraction, the other being fatty acids. The fuel utilized by muscle depends on factors such as the type, intensity and duration of exercise, glycogen being primarily used during short bursts of high-intensity exercise [20]. Glycogen turnover is tightly regulated by two enzymes, GS and GP. PP1 catalyzes the dephosphorylation of GS and GP, thereby activating GS, inactivating GP, and promoting net glycogen synthesis [7,8]. Its activity is regulated by a large family of targeting subunits, of which RGL is the major glycogen targeting subunit in muscle [21]. Several human genetic disorders of glycogen metabolism have been described affecting muscle alone or muscle, liver, and other tissues. Until very recently, all of those affecting muscle alone impaired glycogen breakdown and caused either episodic exercise intolerance or fixed, progressive muscle weakness [20]. Kollberg et al. [22] described a consanguineous kindred in which three individuals were homozygous for premature stop mutations in GYS1. Affected family members presented in childhood with hypertrophic cardiomyopathy (which appeared to cause sudden death in one case) and exercise intolerance. Muscle histology revealed severe glycogen depletion and a marked increase in mitochondria-rich type 1 fibres. Glucose tolerance appeared to be normal in the single individual in whom it was assessed. This human phenotype is similar to that of the GYS1 knockout mice [16,23]. A number of mutations in PPP1R3A have been identified in humans but, to date, none have been convincingly linked to in vivo alterations in glycogen metabolism [9,24-27]. We genotyped 744 nondiabetic adults from the Oxford Biobank in order to (1) assess prevalence rates of the PPP1R3A FS variant in an unselected population and (2) identify carriers of the variant whom we might approach for phenotyping. Prevalence figures of 1.46% are consistent with our original observation of 1.36% prevalence in a Cambridgeshire-based study [1]. Fasting and postprandial muscle glycogen levels were significantly decreased in nondiabetic PPP1R3A FS carriers, making this the second genetic condition known to specifically reduce muscle glycogen accumulation.
###end p 75
###begin p 76
###xml 66 76 66 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 152 154 152 154 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 351 353 351 353 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 492 494 492 494 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 635 637 635 637 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 648 650 648 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b028">28</xref>
###xml 804 806 804 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b028">28</xref>
###xml 1012 1014 1012 1014 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 1162 1164 1162 1164 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 1308 1310 1308 1310 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 109 114 <span type="species:ncbi:10090">mouse</span>
###xml 135 140 <span type="species:ncbi:9606">human</span>
###xml 159 163 <span type="species:ncbi:10090">mice</span>
###xml 250 255 <span type="species:ncbi:9606">human</span>
###xml 499 503 <span type="species:ncbi:10090">mice</span>
###xml 917 923 <span type="species:ncbi:9606">humans</span>
###xml 928 932 <span type="species:ncbi:10090">mice</span>
In order to precisely delineate the molecular consequences of the PPP1R3A FS variant we generated a knock-in mouse model, carrying the human mutation. RGL kin mice were healthy, reproductively viable, and of normal body weight and fat mass, but like human carriers, had significantly decreased skeletal muscle glycogen levels. Although the truncated RGL is expressed at levels similar to the WT allele and retains its capacity to bind PP1c, muscle GS activity was significantly decreased in RGL kin mice and GP activity was increased. In contrast to the apparent susceptibility to degradation of an adenovirally expressed 375-residue RGL fragment [28], we did not detect any evidence of degradation of our 634 amino acid FS variant. It is important to note that degradation was observed by Lerin et al. [28] only when cells were grown under nonphysiological conditions of zero glucose, a state that does not occur in humans and mice. The reduction in GS activity is nicely explained by the failure of truncated RGL to colocalize with GS and therefore to direct PP1c phosphatase activity to GS. As GS is largely bound to glycogen, the inability of the truncated RGL to colocalize with GS, despite the fact that it retains the glycogen-binding domain, suggests that the glycogen-binding affinity of truncated RGL is decreased.
###end p 76
###begin p 77
###xml 143 145 143 145 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 544 546 544 546 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 638 639 638 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b001">1</xref>
###xml 685 687 685 687 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 715 717 715 717 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 779 788 779 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050027-sg003">Figure S3</xref>
###xml 933 935 933 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b018">18</xref>
###xml 1013 1015 1013 1015 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 1095 1097 1095 1097 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 1159 1161 1159 1161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b017">17</xref>
###xml 1272 1274 1272 1274 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 1351 1353 1351 1353 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
This observation is somewhat surprising, but several alternative explanations can be advanced. First, although the glycogen-binding domain in RGL is essential it may not be sufficient and additional sites in the C-terminal third of the protein may also be involved in glycogen binding. Second, deletion of the C-terminal third of the protein may affect the overall protein conformation, impairing binding to glycogen. Third, it is possible that association with the sarcoplasmic reticulum is critical for glycogen binding, since our truncated RGL lacks the C-terminal hydrophobic segment and cannot associate with sarcoplasmic reticulum [1]. However, the sedimentation of full-length RGL and GS, but not truncated RGL, in the high-speed pellet after Triton X-100 solubilisation (Figure S3), argues that binding of the full-length form to glycogen is independent of sarcoplasmic reticulum association. Contrary to previous proposals [18], we also provide compelling evidence that GS does not stably interact with RGL in the physiological tissue. Studies implicating a direct interaction between RGL and GS utilized nonphysiological and overexpressing systems [17]. We used both coimmunoprecipitation and GST pull-down assays to show that neither full length nor truncated RGL binds GS. These observations support the notion that the basic function of RGL is to target PP1c to glycogen, thereby promoting dephosphorylation of glycogen bound GS and GP, a catalytic process that does not require stable interaction.
###end p 77
###begin p 78
###xml 15 25 15 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b029">29</xref>
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b030">30</xref>
###xml 344 354 344 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 435 436 435 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b001">1</xref>
###xml 519 524 519 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 562 567 562 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 690 695 690 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 786 788 786 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b031">31</xref>
###xml 881 891 881 891 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 902 903 902 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b001">1</xref>
###xml 962 972 962 972 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 80 85 <span type="species:ncbi:9606">human</span>
Given that the PPP1R3A FS variant is prevalent in UK white populations and that human physiological studies strongly implicate impaired insulin-stimulated glycogen synthesis in the pathogenesis of insulin-resistant type 2 diabetes [29,30], is there any evidence that it is a significant "diabetes genetic variant"? We originally identified the PPP1R3A FS mutation in a large kindred with severe insulin resistance and type 2 diabetes [1]. In that kindred only those individuals harbouring a second unlinked mutation in PPARG were severely insulin resistant. The PPARG mutation is a loss-of-function mutation, but did not manifest dominant negative activity, which is a feature of the other PPARG variants shown to be associated with partial lipodystrophy and severe insulin resistance [31]. In a second family, weight gain appeared to induce disproportionate insulin resistance in PPP1R3A FS carriers [1]. Taken together, these data suggest that carriers of the PPP1R3A FS variant may be predisposed to develop severe insulin resistance in the setting of adipose tissue dysfunction.
###end p 78
###begin p 79
###xml 64 66 64 66 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 115 117 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b032">32</xref>
###xml 207 216 203 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0050027-sg004">Figure S4</xref>
###xml 445 450 437 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG</italic>
###xml 546 548 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b032">32</xref>
###xml 575 583 563 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARG FS</italic>
###xml 635 637 623 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b031">31</xref>
###xml 887 888 875 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 929 930 917 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b001">1</xref>
###xml 1181 1191 1157 1167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 1411 1413 1387 1389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0050027-b033">33</xref>
###xml 1540 1550 1516 1526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 46 50 <span type="species:ncbi:10090">mice</span>
###xml 71 75 <span type="species:ncbi:10090">mice</span>
###xml 219 224 <span type="species:ncbi:10090">Mouse</span>
###xml 229 234 <span type="species:ncbi:9606">human</span>
###xml 281 286 <span type="species:ncbi:10090">mouse</span>
###xml 331 336 <span type="species:ncbi:9606">human</span>
###xml 395 399 <span type="species:ncbi:10090">mice</span>
###xml 429 435 <span type="species:ncbi:9606">humans</span>
###xml 477 481 <span type="species:ncbi:10090">mice</span>
###xml 559 565 <span type="species:ncbi:9606">humans</span>
###xml 1518 1523 <span type="species:ncbi:9606">human</span>
###xml 1753 1759 <span type="species:ncbi:9606">humans</span>
In an effort to replicate this interaction in mice, we crossed RGL kin mice with PPARgamma heterozygous knockouts [32] but the double heterozygosity failed to alter glucose tolerance or insulin sensitivity (Figure S4). Mouse and human muscle glycogen metabolism is very different (mouse glycogen content is much lower than that of human muscle), and the phenotype of PPARgamma haploinsufficient mice is very different to that of humans with the PPARG FS variant. PPARgamma +/- mice are protected against diet- and age-induced insulin resistance [32], whereas humans with the PPARG FS variant, which appears to behave as a null allele [31], manifest exaggerated hypertriglyceridaemia and insulin resistance with weight gain (unpublished data). Our original studies in Cambridgeshire volunteers did involve individuals with type 2 diabetes and controls, and the variant was significantly (p = 0.03) enriched in the diabetic group [1]. However, given a population prevalence of approximately1.46% and an apparently subtle phenotype, it will require very large population-based studies in multiple ethnic groups to determine whether it has a significant impact on type 2 diabetes. The PPP1R3A FS variant is not captured by existing fixed single nucleotide polymorphism arrays, so one cannot infer anything about its impact on diabetes risk from the recently reported type 2 diabetes genomewide association studies [33]. The FS mutation could also have functional implications for skeletal muscle performance. Anecdotally, human carriers of the PPP1R3A FS variant do not report exercise intolerance or muscle weakness. Studies of exercise tolerance combined with stable isotope tracing of metabolic fluxes will be needed to formally address this question in humans.
###end p 79
###begin p 80
###xml 33 43 33 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A FS</italic>
###xml 248 254 <span type="species:ncbi:9606">humans</span>
###xml 259 263 <span type="species:ncbi:10090">mice</span>
###xml 474 480 <span type="species:ncbi:9606">humans</span>
###xml 638 643 <span type="species:ncbi:9606">human</span>
In summary, we have identified a PPP1R3A FS variant, which encodes a truncated protein that is mistargeted within the cell, that decreases muscle GS activity, and that increases phosphorylase activity, thereby decreasing muscle glycogen content in humans and mice. This metabolic change by itself does not alter glucose tolerance or insulin sensitivity. The findings are notable because this is a prevalent genetic mutation that clearly impairs muscle glycogen synthesis in humans. These data also demonstrate that functionally important mutations occurring at appreciable population frequencies contribute to the genetic architecture of human metabolic variation.
###end p 80
###begin title 81
Supporting Information
###end title 81
###begin title 82
###xml 59 66 59 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppp1r3a</italic>
###xml 53 58 <span type="species:ncbi:10090">Mouse</span>
Strategy for the Generation of the Frameshift Mutant Mouse Ppp1r3a Locus
###end title 82
###begin p 83
(16 KB PDF)
###end p 83
###begin p 84
Click here for additional data file.
###end p 84
###begin title 85
###xml 28 35 28 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppp1r3a</italic>
###xml 38 40 38 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 14 18 <span type="species:ncbi:10090">Mice</span>
Generation of Mice with the Ppp1r3a (RGL) Frameshift Mutation
###end title 85
###begin p 86
(A) Southern blots of initially targeted embryonic stem (ES) cell clones and after Cre recombinase excision of the Neo cassette. Two targeted clones were originally obtained, 1 and 2, which were analyzed by Southern blotting.
###end p 86
###begin p 87
(B) After excision of the Neo cassette, six subclones from each original were analyzed by Southern blotting. Two each are shown.
###end p 87
###begin p 88
###xml 68 70 68 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 86 90 <span type="species:ncbi:10090">mice</span>
(C) PCR genotyping of WT, heterozygous (het), and homozygous (hom) RGL knock-in (kin) mice with a pair of primers straddling the residual loxP site or with a pair of primers that specifically recognize the frameshift mutation. AhdI, Ah; BStz171, Bs; EcoRv, Ec; NcoI, Nc; NheI, Nh; NotI, No; Truncated, Tg, XhoI, Xh.
###end p 88
###begin p 89
(133 KB PDF)
###end p 89
###begin p 90
Click here for additional data file.
###end p 90
###begin title 91
Western Blots of Muscle Extracts
###end title 91
###begin p 92
###xml 138 139 138 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 285 287 285 287 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 329 331 329 331 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 364 366 364 366 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 382 386 <span type="species:ncbi:10090">mice</span>
Muscle extracts were prepared in the presence of 0.2% Triton X-100 to solubilise membranes. High speed (HS) ultracentrifugation at 100,000g for 90 min was used to pellet glycogen before Western blotting of supernatant and pellet fractions for full-length and truncated mutant (trunc) RGL and GS in samples from WT, heterozygous RGL knock-in (het), and homozygous RGL knock-in (hom) mice.
###end p 92
###begin p 93
(71 KB PDF)
###end p 93
###begin p 94
Click here for additional data file.
###end p 94
###begin title 95
Glucose and Insulin Tolerance Tests
###end title 95
###begin p 96
###xml 68 70 68 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 96 98 96 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 185 186 181 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 179 183 <span type="species:ncbi:10090">mice</span>
Glucose tolerance tests (A) and insulin tolerance tests (B) in WT, RGL knock-in heterozygotes (RGL kin het), PPARgamma heterozygous knockouts (PPARg +/-), and doubly heterozygous mice. n = 7-8 per group.
###end p 96
###begin p 97
(16 KB PDF)
###end p 97
###begin p 98
Click here for additional data file.
###end p 98
###begin title 99
Supplementary Experimental Procedures
###end title 99
###begin p 100
(48 KB DOC)
###end p 100
###begin p 101
Click here for additional data file.
###end p 101
###begin title 102
Accession Numbers
###end title 102
###begin p 103
###xml 74 80 74 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3</italic>
###xml 92 104 92 104 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Homo sapiens</named-content>
###xml 162 169 162 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppp1r3a</italic>
###xml 194 206 194 206 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Mus musculus</named-content>
###xml 92 104 <span type="species:ncbi:9606">Homo sapiens</span>
###xml 194 206 <span type="species:ncbi:10090">Mus musculus</span>
The GenBank () accession numbers of the genes discussed in this paper are PPP1R3 (AF024578; Homo sapiens type-1 protein phosphatase skeletal muscle glycogen) and Ppp1r3a (AF309628 and AF309629; Mus musculus type 1 protein phosphatase targeting subunit RGL/ GM gene).
###end p 103
###begin p 104
###xml 42 54 <span type="species:ncbi:9606">participants</span>
The authors would like to acknowledge the participants and their referring physicians.
###end p 104
###begin title 105
Abbreviations
###end title 105
###begin p 106
adenosine monophosphate
###end p 106
###begin p 107
frameshift
###end p 107
###begin p 108
glucose 6-phosphate
###end p 108
###begin p 109
glycogenin
###end p 109
###begin p 110
glycogen phosphorylase
###end p 110
###begin p 111
glycogen synthase
###end p 111
###begin p 112
phosphoprotein phosphatase 1 catalytic subunit
###end p 112
###begin p 113
###xml 91 93 91 93 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
###xml 108 109 108 109 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</sub>
gene encoding the phosphoprotein phosphatase 1 muscle-specific glycogen targeting subunit RGL (also called GM)
###end p 113
###begin p 114
###xml 1 3 1 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GL</sub>
RGL knock-in
###end p 114
###begin p 115
standard error of the mean
###end p 115
###begin p 116
wild type.
###end p 116
###begin title 117
References
###end title 117
###begin article-title 118
###xml 54 59 <span type="species:ncbi:9606">human</span>
Digenic inheritance of severe insulin resistance in a human pedigree
###end article-title 118
###begin article-title 119
Gene structure and expression of the targeting subunit, RGL, of the muscle-specific glycogen-associated type 1 protein phosphatase, PP1G
###end article-title 119
###begin article-title 120
On target with a new mechanism for the regulation of protein phosphorylation
###end article-title 120
###begin article-title 121
Molecular cloning and expression of the regulatory (RG1) subunit of the glycogen-associated protein phosphatase
###end article-title 121
###begin article-title 122
Protein phosphatase type-1 and glycogen bind to a domain in the skeletal muscle regulatory subunit containing conserved hydrophobic sequence motif
###end article-title 122
###begin article-title 123
Structural basis for the recognition of regulatory subunits by the catalytic subunit of protein phosphatase 1
###end article-title 123
###begin article-title 124
Organizing glucose disposal: emerging roles of the glycogen targeting subunits of protein phosphatase-1
###end article-title 124
###begin article-title 125
The structure and regulation of protein phosphatases
###end article-title 125
###begin article-title 126
Glycogen and its metabolism
###end article-title 126
###begin article-title 127
###xml 51 55 <span type="species:ncbi:10090">mice</span>
Insulin control of glycogen metabolism in knockout mice lacking the muscle-specific protein phosphatase PP1G/RGL
###end article-title 127
###begin article-title 128
The muscle-specific protein phosphatase PP1G/R(GL)(G(M))is essential for activation of glycogen synthase by exercise
###end article-title 128
###begin article-title 129
The in vivo effects of the Pro12Ala PPARgamma2 polymorphism on adipose tissue NEFA metabolism: the first use of the Oxford Biobank
###end article-title 129
###begin article-title 130
Direct assessment of muscle glycogen storage after mixed meals in normal and type 2 diabetic subjects
###end article-title 130
###begin article-title 131
A rapid filter paper assay for UDPglucose-glycogen glucosyltransferase, including an improved biosynthesis of UDP-14C-glucose
###end article-title 131
###begin article-title 132
Radioactive method for the assay of glycogen phosphorylases
###end article-title 132
###begin article-title 133
###xml 22 26 <span type="species:ncbi:10090">mice</span>
Glucose metabolism in mice lacking muscle glycogen synthase
###end article-title 133
###begin article-title 134
###xml 58 65 58 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3A</italic>
###xml 75 79 <span type="species:ncbi:10090">mice</span>
Metabolic switch in glycogen deficient skeletal muscle of PPP1R3A knockout mice
###end article-title 134
###begin article-title 135
Glycogen synthase association with the striated muscle glycogen-targeting subunit of protein phosphatase-1. Synthase activation involves scaffolding regulated by beta-adrenergic signaling
###end article-title 135
###begin article-title 136
Interaction between glycogenin and glycogen synthase
###end article-title 136
###begin article-title 137
Muscle glycogenoses
###end article-title 137
###begin article-title 138
Protein phosphatase 1 binding proteins
###end article-title 138
###begin article-title 139
Cardiomyopathy and exercise intolerance in muscle glycogen storage disease 0
###end article-title 139
###begin article-title 140
Abnormal cardiac development in the absence of heart glycogen
###end article-title 140
###begin article-title 141
A type 2 diabetes-associated polymorphic ARE motif affecting expression of PPP1R3 is involved in RNA-protein interactions
###end article-title 141
###begin article-title 142
A widespread amino acid polymorphism at codon 905 of the glycogen-associated regulatory subunit of protein phosphatase-1 is associated with insulin resistance and hypersecretion of insulin
###end article-title 142
###begin article-title 143
###xml 96 104 <span type="species:ncbi:9606">patients</span>
Association of muscle glycogen synthase polymorphism with insulin resistance in type 2 diabetic patients
###end article-title 143
###begin article-title 144
Polymorphism of the glycogen synthase gene and non-insulin-dependent diabetes mellitus
###end article-title 144
###begin article-title 145
###xml 98 103 <span type="species:ncbi:9606">human</span>
Regulation and function of the muscle glycogen-targeting subunit of protein phosphatase 1 (GM) in human muscle cells depends on the COOH-terminal region and glycogen content
###end article-title 145
###begin article-title 146
Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy
###end article-title 146
###begin article-title 147
Cellular mechanisms of insulin resistance
###end article-title 147
###begin article-title 148
###xml 36 41 <span type="species:ncbi:9606">human</span>
Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance
###end article-title 148
###begin article-title 149
Effect of heterozygous PPARgamma deficiency and TZD treatment on insulin resistance associated with age and high-fat feeding
###end article-title 149
###begin article-title 150
Genome-wide association studies provide new insights into type 2 diabetes aetiology
###end article-title 150
###begin p 151
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author Contributions.</bold>
###xml 22 27 <span type="species:ncbi:10090">Mouse</span>
###xml 139 144 <span type="species:ncbi:9606">Human</span>
Author Contributions. Mouse studies were designed and performed by DBS, LZ, CSC, ACG, SEW, GMG, SK, CBB, DMS, AVP, GIS, BAP, PJR and ADPR. Human studies were designed and performed by DBS, BR, JES, NJW, FK, RT and SOR. The manuscript was prepared by DBS, SOR and ADPR, and seen by all authors.
###end p 151
###begin p 152
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding:</bold>
###xml 13 18 <span type="species:ncbi:10090">mouse</span>
Funding: The mouse work was supported by National Institutes of Health grants R01-DK036569 to ADPR and R01 DK-40936, U24 DK-59635, and a Distinguished Clinical Investigator Award from the ADA to GIS. DBS, FK, and SOR are supported by the Wellcome Trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 152
###begin p 153
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests:</bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 153

